Square Pharma’s Record 130% Cash Dividend: What the FY26 Numbers Tell Investors
Square Pharmaceuticals PLC, one of the largest companies on the Dhaka Stock Exchange, has recommended a 130% cash dividend — Tk 13 per share — for the fiscal year ended 30 June 2026 (FY26). It is the highest dividend in the company’s history, backed by a record consolidated net profit of Tk 2,770 crore.
FY26 at a glance
| Item | FY26 | FY25 | Change |
|---|---|---|---|
| Cash dividend | 130% (Tk 13/share) | 120% (Tk 12/share) | +Tk 1 |
| Consolidated net profit | Tk 2,770 crore | Tk 2,396 crore | +16% |
| Revenue | Tk 8,606 crore | Tk 7,628 crore | ≈ +13% |
| Earnings per share (EPS) | Tk 31.24 | Tk 27.04 | +16% |
| Net asset value (NAV) per share | Tk 178.99 | Tk 157.88 | +13% |
| Net operating cash flow per share (NOCFPS) | Tk 18.65 | — | — |
Key dates for shareholders
- Record date: 16 November 2026. Only shareholders whose names are in the register on this date receive the dividend.
- Annual General Meeting: 15 December 2026. The dividend is a board recommendation until shareholders approve it at the AGM.
Because DSE trades take time to settle, buying on or right before the record date may be too late to qualify. If you want the dividend, check the last eligible trading day with your trader — and remember that share prices usually adjust downward after the record date to reflect the dividend being paid out.
A steady dividend track record
The FY26 payout continues a rising run of cash dividends:
| Fiscal year | Cash dividend | Per share |
|---|---|---|
| FY26 | 130% | Tk 13.00 |
| FY25 | 120% | Tk 12.00 |
| FY24 | 110% | Tk 11.00 |
| FY23 | 105% | Tk 10.50 |
Profit has grown alongside: consolidated net profit rose from Tk 1,817 crore in FY22 to Tk 2,770 crore in FY26 — roughly 11% a year compounded. Steady, rising cash dividends paid out of growing profits are one of the clearest signs of a financially healthy company.
What the numbers mean
Using the closing price of Tk 218.80 on 26 October 2026, here is how the results translate into common valuation measures:
- Dividend yield ≈ 5.9%. Tk 13 ÷ Tk 218.80. Remember: a “130% dividend” is 130% of the Tk 10 face value, not of the price you pay. Your actual cash return depends on your purchase price.
- Price-to-earnings (P/E) ≈ 7.0x. Tk 218.80 ÷ Tk 31.24 EPS.
- Price-to-book (P/B) ≈ 1.2x. Tk 218.80 ÷ Tk 178.99 NAV per share.
- Payout ratio ≈ 42%. Tk 13 ÷ Tk 31.24 — the company pays out less than half its earnings and keeps the rest to reinvest, including a newly approved Tk 725 crore investment in modernisation, expansion, machinery and land.
One figure worth watching: NOCFPS of Tk 18.65 is lower than EPS of Tk 31.24. Part of Square’s consolidated profit comes from its subsidiaries and associates — including Square Pharmaceuticals Kenya EPZ, Square Lifesciences, Square Textiles, Square Fashions and Square Hospitals — and investment-related income does not always show up as operating cash. Comparing cash flow with profit over several years is a good habit for any company you own.
How Square has been performing: what the press and analysts say
The record dividend is the end point of several years of steady growth that Bangladesh’s business press and brokerage analysts have tracked closely.
Market leader by a clear margin
Square is Bangladesh’s largest drug maker. A BRAC EPL Investments equity note, citing IQVIA data for FY2025, puts its market share at 17.4%, ahead of Incepta (12.8%) and Beximco Pharma (9.6%). The company makes more than 500 products across 33+ dosage forms, from antibiotics and cardiovascular medicines to oncology and animal health. It is approved to export to regulated markets including the USA, EU, UK and Australia, and now sells in more than 40 countries.
FY25: the first Tk 2,400 crore year
The Daily Star reported that in FY25 Square and its associates crossed Tk 2,400 crore in profit for the first time in the company’s history. Overall profit rose 15% to Tk 2,397 crore on sales of about Tk 7,628 crore (+9%). Profit from associates rose 23% to about Tk 320 crore, investment income rose about 34% to Tk 620 crore, and finance costs fell.
FY26: growth through the year
- Nine months to March 2026: The Financial Express reported profit of Tk 2,064 crore (+10%) on revenue of Tk 6,508 crore (+12.5%). Local sales grew more than 9%, revenue at the Kenya subsidiary rose 4.5%, and finance costs fell 55% after partial repayment of long-term loans.
- Full year: Profit growth then picked up to 16% for the full year (18% by The Daily Star’s measure), pointing to a strong April–June quarter.
- Analyst view: Akramul Alam of Royal Capital told The Financial Express that the company “continues to grow in both sales and profit owing to strong consumer trust in its products,” and pointed to Square’s ability to make quality generics at relatively low cost.
New growth engines
According to the BRAC EPL note, Square Lifesciences, its animal-health business, grew revenue 52% to about Tk 1,650 crore in FY25. The Kenya subsidiary’s revenue roughly tripled (+201%) to about Tk 69 crore. Together with the newly approved Tk 725 crore investment in capacity, these give Square more avenues for growth beyond its core domestic pharma business.
How it compares with peers
Being the largest also means growing from a bigger base. In the July–March period, The Financial Express noted that Square’s 10% profit growth trailed several smaller peers, including Renata (+28%), IBN Sina (+33%) and Beacon (+59%). Across eight major listed drug makers, combined profit rose about 14% and sales 13%. The industry as a whole meets about 98% of local demand. Square’s strength is not the fastest growth but consistency, scale and a balance sheet that can fund both expansion and rising dividends.
Risks analysts flag
- Margin pressure: Gross margin slipped from 54.1% in FY2022 to 50.1% in FY2025, per BRAC EPL.
- Import dependence: About 30% of raw materials (APIs) are imported, mainly from India and China. This leaves costs exposed to taka depreciation.
- Competition: Mid-tier local manufacturers are growing faster.
- Idle cash: BRAC EPL analysts argue that Square’s large cash and investment pile, more than Tk 5,500 crore, holds down return on equity (15.6% in FY25).
Tax on the dividend
Cash dividends are paid after tax deducted at source. Under the FY2026-27 budget, dividend income for individuals is taxed at 15%. Keep your e-TIN updated with your broker so the correct rate applies. Read our full guide: Tax on share investment in Bangladesh.
The bigger picture
Square Pharma is a reminder of how long-term wealth is usually built on the DSE: owning businesses that grow their profits year after year and share them with investors through rising cash dividends. In a market where many companies pay little or nothing, a consistent dividend payer with growing earnings stands out.
That said, a strong year is not a guarantee of future returns. Pharmaceutical companies face regulatory, pricing and raw-material cost risks, and any single stock should be one part of a diversified portfolio.
You can track SQURPHARMA’s live price, market depth, chart and company news in the Amar Biniyog app. New to investing? Open a BO account online and read our beginner’s guide to the Bangladesh stock market.
Sources: The Business Standard, 26 October 2026; The Daily Star, 27 October 2026; The Daily Star, “Square makes Tk 2,400 crore profit for first time”; The Financial Express, 4 May 2026; BRAC EPL Investments, SQURPHARMA equity note; Simply Wall St. Valuation ratios are Amar Biniyog’s own calculations from the reported figures and the 26 October closing price.
This article is for general education only and is not investment advice or a recommendation to buy or sell any security. Investment in the capital market carries risk; past performance does not guarantee future returns.